Exelixis Says U.S. Court Of Appeals For Federal Circuit Affirms Key Portion Of 2024 Judgment In Co's Favor
EXEL•Federal Circuit affirms key portion of patent ruling
Aug. 31 (Reuters) - Exelixis Inc. EXEL.O:
- Exelixis announces update on patent litigation trial appeal with MSN Laboratories
- Exelixis - U.S. Court of Appeals for the Federal Circuit affirms key portion of 2024 judgment in Exelixis' favor
- Exelixis - MSN may launch generic cabozantinib in U.S. no earlier than January 15, 2030
- Exelixis - MSN launch depends on litigation over patent 12,128,039; trial begins November 2026
Source text: ID:nBw5Fkcga
Further company coverage: EXEL.O
